Abstract
Background: The potential association between preoperative percutaneous transthoracic needle biopsy (PTNB) and pleural recurrence in lung cancer remains controversial. This study aimed to determine whether PTNB increases the risk of pleural recurrence in patients with clinically diagnosed stage I non-small cell lung cancer (NSCLC). Methods: We retrospectively analyzed 1,733 patients with clinical stage I NSCLC who underwent surgical resection between January 2018 and December 2020. Patients were divided into the PTNB group (n=699) and the non-PTNB group (n=1,034). After 1:1 propensity score matching (PSM), risk factors for pleural recurrence were assessed using Fine-Gray subdistribution hazard models. Cumulative incidence rate and overall survival (OS) were also analyzed. Results: After matching, 530 patients were included in each group. Multivariate Fine-Gray analysis revealed that PTNB [subdistribution hazard ratio (sHR) =3.74; 95% confidence interval (CI): 1.06–13.20; P=0.040] and visceral pleural invasion (VPI) (sHR =3.12; 95% CI: 1.10–8.90; P=0.03) were independent risk factors for isolated pleural recurrence, whereas lymphatic invasion was not (sHR =2.32; 95% CI: 0.82–6.56; P=0.11). For all types of recurrence, PTNB, VPI, and lymphatic invasion were significant predictors (all PConclusions: Preoperative PTNB was statistically correlated with an increased pleural recurrence in clinical stage I NSCLC, even among patients without conventional high-risk pathological features. Careful consideration is warranted when deciding on PTNB for early-stage disease.

This publication has 23 references indexed in Scilit: